Ekso Bionics Holdings, Inc. Announces Executive Changes
November 05, 2018 at 08:32 am EST
Share
On October 30, 2018, the Board of Directors of Ekso Bionics Holdings, Inc. appointed Thomas A. Schreck to fill the vacancy created by the foregoing increase. Mr. Schreck will serve as a member of the Audit Committee of the Board, the Chair of the Compensation Committee of the Board and the Chair of the Nominating and Governance Committee of the Board. Mr. Schreck he has served as the co-founder, Vice Chairman and Chief Executive Officer of Sinusys Corp. From July 2005 to June 2010, Mr. Schreck served as the co-founder, Chairman of the Board and Chief Executive Officer of AcelRx Pharmaceuticals, Inc. Also on October 30, 2018, the Board approved the appointment of Steven Sherman, previously the Chairman of the Board, as the company’s Executive Chairman, effective as of October 30, 2018 and with initial service for a two-year term. As Executive Chairman, Mr. Sherman will advise the Company’s Chief Executive Officer regarding strategic business development activities, and Mr. Sherman will no longer serve on the Company’s Audit Committee, Compensation Committee or Nominating and Governance Committee. Mr. Sherman is 73 years old and has served as a director and the Chairman of the Board since January 2014, and served on the board of directors of Ekso Bionics, Inc. from December 2013 until January 2014.
Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.
EKSO BIONICS HOLDINGS, INC. 
